A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<；5 μm and Dv50<；1 μm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.
